TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7875666
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose cefotaxime (2 g every 6 hours)
Study: 7875666
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose cefotaxime (2 g every 12 hours)
Study: 2087437
Drug: Saline (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (0.2 ml)
Study: 35195
Drug: Clobazam 15
Normalized name: Clobazam
DrugBank: Clobazam (DB00349)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clobazam 15 mg daily
Study: 35195
Drug: Clobazam 30
Normalized name: Clobazam
DrugBank: Clobazam (DB00349)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clobazam 30 mg daily
Study: 35195
Drug: Diazepam 15
Normalized name: diazepam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 15 mg daily
Study: 25575616
Drug: Methylphenidate transdermal
Normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate transdermal delivery system (MTS)
Study: 11967499
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (CEE) 0.625 mg
Study: 15172084
Drug: CEE +
Normalized name: Conjugated Estrogen Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE + medroxyprogesterone acetate (CEE/MPA) 5 mg
Study: 11800516
Drug: Insulin-like growth
Normalized name: Insulin-like growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-like growth factor-I treatment
Study: 9591509
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of estradiol and progesterone
Study: 7882660
Drug: Continuing education
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing education intervention 'Periodontics in General Practice' including a 1-day seminar, bi-monthly newsletters, individualized 3-monthly comparative feedback, and technical assistance.
Study: 3255811
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (liquid nitrogen + wart paint)
Study: 3255811
Drug: Liquid nitrogen
DrugBank: Nitrogen (DB09152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liquid nitrogen applied weekly
Study: 3255811
Drug: Daily application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily application of wart paint (lactic acid one part, salicylic acid one part, collodion four parts)
Study: 27979383
Drug: Atezolizumab 1200
Normalized name: atezolizumab 1200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab 1200 mg every 3 weeks
Study: 23666379
Drug: Focused Shockwave
Normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focused Shockwave Therapy (FSWT)
Study: 23666379
Drug: Radial Shockwave
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial Shockwave Therapy (RSWT)
Study: 23536950
Drug: Succinate-containing dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinate-containing dialysis solution (SCDS)
Study: 23536950
Drug: Standard bicarbonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard bicarbonate dialysis solution
Study: 19453400
Drug: Inactivated, aluminium‐adjuvanted,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated, aluminium‐adjuvanted, whole‐virion prototype pandemic influenza A (H5N1) vaccine (PanFlu)
Study: 17211365
Drug: Dicumarol therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dicumarol therapy suspended and replaced by heparin-calcium in group D (control group)
Study: 12950426
Drug: Lumiracoxib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumiracoxib 200 mg twice daily for 8 days
Study: 12950426
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg twice daily for 8 days
Study: 3533755
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil ester (1.5 g) with probenecid (1.0 g)
Study: 3533755
Drug: Amoxycillin (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (3.0 g) plus clavulanic acid (0.25 g) with probenecid (1.0 g)
Study: 17319482
Drug: Single-dose extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose extended-release epidural morphine (EREM) 10, 20, or 30 mg
Study: 12714115
Drug: Aspirin (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (low dose of 100mg daily or less)
Study: 12714115
Drug: NSAIDs without
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NSAIDs without aspirin
Study: 12714115
Drug: Aspirin (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (for individuals aged 75 years and over)
Study: 12714115
Drug: Aspirin (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (for individuals younger than 75 years)
Study: 1539812
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl administration
Study: 1539812
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl administration
Study: 1539812
Drug: Both epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both epidural and intravenous fentanyl
Study: 30396739
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation preoperatively
Study: 26853645
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard treatment with compression stockings and anticoagulants)
Study: 23446197
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate (PP; 234 mg day 1 and 156 mg day 8)
Study: 23446197
Drug: Risperidone long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone long-acting injection (RLAI; 25 mg, days 8 and 22)
Study: 22836068
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus colesevelam (3.75 g/day)
Study: 6371696
Drug: Antenatal corticosteroids
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal corticosteroids (steroids)
Study: 28805455
Drug: Telephone-based peer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based peer support intervention (weekly calls for six weeks)
Study: 27087149
Drug: AMA1 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMA1 vaccine candidate
Study: 19926634
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid 15 mg/kg given at skin incision and 3 hours later
Study: 16145639
Drug: 0.125 %
Normalized name: kinetin 0.125 % Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 % bupivacaine plus 1 microg x ml (‐1) fentanyl
Study: 16145639
Drug: 0.125 %
Normalized name: kinetin 0.125 % Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 % bupivacaine plus 0.75 microg x ml (‐1) clonidine
Study: 12116326
Drug: Pulsed Nd:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed Nd:YAG laser treatment
Study: 12116326
Drug: Drill treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drill treatment
Study: 2286697
Drug: Titrated dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated dose of midazolam to produce light or heavy sedation
Study: 2286697
Drug: Midazolam (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (all treatment levels)
Study: 31336184
Drug: Luteal phase
Normalized name: Nuphar lutea leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteal phase support with hCG (1500 IU, two injections at three days interval)
Study: 24178807
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg intravitreal triamcinolone acetonide (IVTA) injection
Study: 21862138
Drug: Bupropion 300
Normalized name: buPROPion 300 mg/24 hours oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion 300 mg daily
Study: 15292314
Drug: pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: pioglitazone (30 mg/d)
Study: 17482941
Drug: Verapamil 10
Normalized name: verapamil 100 mg/24 hours oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 10 mg/20 mL (Group 3)
Study: 17482941
Drug: Verapamil 10
Normalized name: verapamil 100 mg/24 hours oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 10 mg/4 mL (Group 1)
Study: 17482941
Drug: Verapamil 10
Normalized name: verapamil 100 mg/24 hours oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 10 mg/10 mL (Group 2)
Study: 14693983
Drug: Inhaled fast‐acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fast‐acting human insulin via AERx iDMS
Study: 14693983
Drug: Subcutaneous fast‐acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous fast‐acting human insulin
Study: 9795350
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg prednisolone twice daily
Study: 7986457
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of antihypertensive medication with no dietary intervention
Study: 7986457
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of antihypertensive medication with sodium restriction
Study: 7986457
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of antihypertensive medication with weight reduction for the obese
Study: 7986457
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (return to antihypertensive medication)
Study: 2590608
Drug: Intravenous oxpentifylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous oxpentifylline (200 mg in 10 ml saline)
Study: 19101099
Drug: Motivation Enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivation Enhancement Therapy (MET)
Study: 19657294
Drug: Antioxidants (AOX)
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidants (AOX) supplementation (272 mg of alpha‐tocopherol, 400 mg of vitamin C, 30 mg of beta‐carotene, 2 mg of lutein, 400 mcg of selenium, 30 mg of zinc, and 600 mg of magnesium)
Study: 15286093
Drug: Hydroxyzine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine 30 mg (positive control)
Study: 8340309
Drug: Fenfluramine (gradually
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine (gradually increased to 1.5 mg/kg/day)
Study: 21078810
Drug: Prescription omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription omega-3 (8 g/d for the first 7 days, then 4 g/d through week 24)
Study: 21078810
Drug: Prescription omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription omega-3
Study: 8908223
Drug: Propofol induction
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol induction at 133 mg · min‐1
Study: 6126399
Drug: Oxatomide (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxatomide (60 mg daily)
Study: 6126399
Drug: Mequitazine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mequitazine (10 mg daily)
Study: 28357404
Drug: Pulsed radiofrequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed radiofrequency (PRF) combined with pharmacological therapy
Study: 24274317
Drug: Proposed herbal
Normalized name: Propoven
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proposed herbal moisturising cream containing Arctium lappa L. seed extract
Study: 15983823
Drug: Orange juice
Normalized name: Orange juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orange juice (200 ml) with atenolol (50 mg)
Study: 15983823
Drug: Water (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (200 ml) with atenolol (50 mg)
Study: 2400198
Drug: lacidipine 4
Normalized name: lacidipine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lacidipine 4 mg b.i.d.
Study: 2400198
Drug: nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine 10 mg b.i.d.
Study: 2400198
Drug: diltiazem 120
Normalized name: diltiazem 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: diltiazem 120 mg b.i.d.
Study: 367025
Drug: Subcutaneous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous low-dose calcium heparin
Study: 367025
Drug: Subcutaneous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous low-dose sodium heparin
Study: 31916704
Drug: NRL-1 (intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRL-1 (intranasal diazepam) 5 mg
Study: 31916704
Drug: NRL-1 (intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRL-1 (intranasal diazepam) 10 mg
Study: 31916704
Drug: NRL-1 (intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRL-1 (intranasal diazepam) 20 mg
Study: 31916704
Drug: NRL-1 (intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRL-1 (intranasal diazepam) 2 x 10 mg
Study: 31916704
Drug: NRL-1 (intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRL-1 (intranasal diazepam)
Study: 31034106
Drug: Exercise and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise and cognitive behavioural therapy treatment
Study: 28697043
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol (OE) 2 mg/day
Study: 28697043
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol (OE) 2 mg/day + medroxyprogesterone acetate (MPA) 5 mg/day
Study: 28697043
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol 1 mg/day
Study: 3292711
Drug: Postmastectomy radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postmastectomy radiation added to chemotherapy
Study: 30580488
Drug: 10-mL syringe
Normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-mL syringe
Study: 23798329
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy for patients aged < 50 years
Study: 23798329
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy for patients aged ≥ 50 years
Study: 23798329
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy for patients aged 50 to 54 years
Study: 23798329
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy for patients aged 55 to 59 years
Study: 23798329
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy for patients aged 60 to 64 years
Study: 10932443
Drug: Integrated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated treatment program for dual disorders (12 months duration)
Study: 1436364
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment without dural closure
Study: 6373685
Drug: Misonidazole (radiosensitizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misonidazole (radiosensitizing drug)
Study: 25643432
Drug: Low-dose intracoronary
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intracoronary UFH (1,000 IU intracoronary UFH)
Study: 25643432
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (70-100 IU/kg intravenous UFH)
Study: 11558045
Drug: 0.5 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 Gy (placebo dose)
Study: 7514356
Drug: Continuous IV
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous IV infusion of ketorolac
Study: 31748208
Drug: Platelet rich
Normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet rich plasma injection
Study: 31748208
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection (dry needle)
Study: 28894836
Drug: Tinnitus Retraining
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinnitus Retraining Therapy (TRT) consisting of directive counseling and acoustic enrichment using combination hearing aids and sound generators
Study: 28894836
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care treatment (SC) consisting of general aural rehabilitation counseling and hearing aids
Study: 22930403
Drug: Curcuminoids (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuminoids (300 mg/day)
Study: 21810242
Drug: Training and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training and guidelines for nurse ART prescription, local management teams, and implementation toolkit.
Study: 8466742
Drug: Isradipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (2.5 mg once daily)
Study: 8466742
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg once daily) added to nitrendipine
Study: 8466742
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg once daily) added to isradipine
Study: 27274349
Drug: Cotton-roll vibration
Normalized name: Cotton
DrugBank: Cotton (DB10707)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotton-roll vibration method (a combination of topical anesthesia gel, cotton roll, and vibration for physical distraction)
Study: 27274349
Drug: Routine topical
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine topical anesthesia (control)
Study: 18445178
Drug: Captopril (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (100 mg) with low-dose bendroflumethiazide (1.25 mg)
Study: 8251413
Drug: Schedule M
Normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule M (intermediate dose methotrexate with folinic acid rescue)
Study: 3895828
Drug: Routine duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine duration of oral anticoagulation (standard duration)
Study: 3895828
Drug: 50% reduction
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% reduction in duration of oral anticoagulation (reduced duration)
Study: 30167675
Drug: Dextroamphetamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine (10 mg) combined with physical therapy
Study: 30167675
Drug: Placebo combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo combined with physical therapy
Study: 27861718
Drug: Cognitively stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitively stimulating activities (daily for up to 30 days)
Study: 27781421
Drug: Fosdagrocorat 5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosdagrocorat 5, 10, or 30 mg (single doses)
Study: 27781421
Drug: Fosdagrocorat 20
Normalized name: Fosdagrocorat
DrugBank: Fosdagrocorat (DB12198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosdagrocorat 20 mg QD (multiple doses for 12 days)
Study: 1854464
Drug: Placebo (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (single and multiple doses)
Study: 16172794
Drug: Toremifene 60
Normalized name: toremifene 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene 60 mg/day
Study: 10587476
Drug: (R)-salbutamol 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: (R)-salbutamol 1.25 mg
Study: 10587476
Drug: (RS)-salbutamol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: (RS)-salbutamol 2.5 mg
Study: 1751787
Drug: Immunoglobulin G
Normalized name: immunoglobulin G
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoglobulin G (400 mg/kg body wt)
Study: 1751787
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline; 8 mL/kg body wt)
Study: 1751787
Drug: Immunoglobulin G
Normalized name: immunoglobulin G
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoglobulin G
Study: 7076630
Drug: Fluphenazine decanoate
Normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine decanoate (continued treatment)
Study: 31030872
Drug: Infant Behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant Behavior Program (a brief, home‐based adaptation of the child‐directed interaction phase of parent‐child interaction therapy)
Study: 28273891
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (350 mg daily for 24 weeks)
Study: 10491058
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of strontium salts
Study: 2140743
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg b.i.d.)
Study: 31287117
Drug: Montmorency tart
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montmorency tart cherry juice (2 cups daily for 12 weeks)
Study: 10686535
Drug: Cladribine (exact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cladribine (exact dosage and duration not available)
Study: 10686535
Drug: Interferons (exact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferons (exact dosage and duration not available)
Study: 9296731
Drug: Multivitamin consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin consumption including 0.8 mg folic acid
Study: 1592976
Drug: Dentifrice formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dentifrice formulations containing NaF, xylitol, or NaF/xylitol
Study: 30275698
Drug: Eplerenone 100
Normalized name: eplerenone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 100 mg daily